Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the ...

Agios Pharmaceuticals Inc. reported top-line data from its 52-week Rise Up trial testing oral pyruvate kinase activator mitapivat in sickle cell disease (SCD), which hit statistical significance on ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

Agios Pharmaceuticals said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but failed to show a statistically significant ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Jayden Wilsey was the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease after federal approval in 2024.

Amy Cohen of Lynn will be running in the New York Road Runners New York City Marathon. She's running as a member of "Team Inspire" because of her extraordinary story. Cohen has sickle cell disease, a ...

It is described as intense pain shooting throughout your body and has had a history of misdiagnosis and complications as patients are constantly traveling to emergency rooms to seek relief. An ...

SOUTH LAKE TAHOE, Calif./STATELINE, Nev.―Gates and facilities close for the winter season at Van Sickle Bi-State Park on November 1, 2025, announced the California Tahoe Conservancy and Nevada ...